Proxy Votes Now

Home › Upcoming votes › Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. Annual Meeting December 14, 2026: What's on the Ballot

Say on paySignificant dissent last year

Prior-year votes at Ensysce Biosciences, Inc. → 2025-2026 season, in the search

Read the proxy statement on EDGAR

Proxy summary

Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.

Virtual annual meeting with nine proposals: a Series C conversion share issuance, a reverse stock split, more authorized shares, an equity plan increase, two directors, say-on-pay and frequency, auditor and adjournment.

Key points

What changed from last year

Last year’s votes

What’s on the ballot

Ballot read from the proxy statement and checked. As listed in Ensysce Biosciences, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.

#ItemProposed byBoard recommendsLast year (same kind of item)
1 Approve full issuance of common stock upon conversion of Series C Preferred Stock (Nasdaq Rules 5635(a) and 5635(b)) Board For —
2 Charter amendment to effect a reverse stock split (1-for-10 to 1-for-30) Board For —
3 Charter amendment to increase authorized common stock from 250,000,000 to 500,000,000 shares Board For —
4 Amendment to the Amended and Restated 2021 Omnibus Incentive Plan to increase shares Board For —
5 Election of two Class II directors
Director election
Board For 2 nominees; support 70% to 70%
6 Advisory vote on named executive officer compensation
Say on pay
Board For —
7 Advisory vote on frequency of say-on-pay votes
Say-on-pay frequency
Board 3 years —
8 Ratification of Baker Tilly US, LLP as independent registered public accounting firm for 2026
Auditor
Board For 94% support
9 Adjournment proposal
Adjournment
Board For —

Last year’s official results

From Ensysce Biosciences, Inc.’s Form 8-K, filed January 8, 2026, for the meeting held January 7, 2026 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.

ItemSupport (of votes cast)Reported outcome
The stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock and exerc73%Approved
2. The amendment of the Ensysce Biosciences, Inc60%Approved
Elect Director: William Chang70%—
Elect Director: Lee Rauch70%—
4. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December94%Approved

Filings for this meeting

About this page

The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.